肺炎支原体感染致慢性咳嗽患儿行孟鲁司特联合布地奈德的疗效

Efficacy of Montelukast Combined with Budesonide in Children with Chronic Cough Caused by Mycoplasma Pneumoniae Infection

目的:探究孟鲁司特联合布地奈德用于肺炎支原体感染致慢性咳嗽患儿中的效果。方法:选取2021年5月—2022年7月上蔡县人民医院收治的80例肺炎支原体感染致慢性咳嗽患儿作为研究对象,随机分为两组,每组各40例。对照组患儿应用布地奈德治疗,试验组患儿应用孟鲁司特联合布地奈德治疗,比较治疗情况。结果:治疗后,咳嗽缓解时间、退热缓解时间及住院时间相比,试验组患儿短于对照组,差异有统计学意义(t=13.019、24.150、7.925,P<0.05);治疗后,试验组患儿炎性因子水平均优于对照组,差异有统计学意义(t=20.122、7.392、15.313、20.243、19.004,P<0.05);治疗后,试验组患儿指标水平低于对照组,差异有统计学意义(t=4.059、7.607、11.718,P<0.05);治疗后,肺功能指标相比,试验组患儿较对照组优,差异有统计学意义(t=4.044、6.081、4.153,P<0.05);试验组患儿治疗有效率为95.0%,高于对照组的77.5%,差异有统计学意义(χ^(2)=5.165,P<0.05)。结论:肺炎支原体感染致慢性咳嗽患儿运用孟鲁司特联合布地奈德治疗,效果显著。

Objective:To investigate the effect of Montelukast combined with budesonide in children with chronic cough caused by Mycoplasma pneumoniae infection.Methods:80 children with chronic cough caused by mycoplasma pneumoniae infection admitted to the hospital from May 2021 to July 2022 were randomly divided into 2 groups,with 40 cases in each group.Control group was treated with budesonide,and experimental group was treated with montelukast combined with budesonide.The treatment situation was compared.Results:After treatment,symptom remission and hospital stay in the experimental group were shorter than those in the control group,and the difference was statistically significant(t=13.019,24.150,7.925;P<0.05).The levels of inflammatory factors in experimental groups were better than those in control group,and the difference was statistically significant(t=20.122,7.392,15.313,20.243,19.004;P<0.05).After treatment,the indexes above in the experimental group were lower than those in the control group,with statistically significant difference(t=4.059,7.607,11.718;P<0.05).After treatment,the experimental group was better than the control group in lung function index,and the difference was statistically significant(t=4.044,6.081,4.153;P<0.05).The effective rate of the experimental group was 95.0%,which was higher than that of the control group(77.5%),and the difference was statistically significant(χ^(2)=5.165,P<0.05).Conclusion:Montelukast combined with budesonide in the treatment of chronic cough caused by mycoplasma pneumoniae infection is effective.